Daniel Weddle

What an interesting read on the shift from traditional patient recruitment methods in rare disease! Learn more about how to optimize patient-driven site engagement in my team member’s blog: https://bit.ly/4eHoBn4

3

A Curative Solution: How Cell & Gene Therapies Support Patients & NJ’s Life Sciences Industry https://ow.ly/xOPe50UnvNc #CellTherapy #GeneTherapy #LifeSciences #Biotech #HealthcareInnovation #PatientCare #NewJerseyLifeSciences

2

In #NeurodegenerativeDisease news, specifically on an experimental treatment for #ALS, with this new #strategic partnership is penned between Dewpoint Therapeutics and Mitsubishi Tanabe Pharma America. ⚛️ The asset is the former's drug, designed "to address the accumulation of a protein into toxic structures that lead to neuronal dysfunction in people with ALS." 🤝 The alliance would grant MTP exclusive rights to license, upon achieving certain developmental milestones. ⚕️ This would add to MTP's existing US-marketed ALS treatment, #Radicava https://lnkd.in/evayrVv4' #Dewpoint #Mitsubishi #Pharma #Biopharma #Healthcare

6

We look forward to hearing Christine Rothe, CDO of iOmx, speak at the 6th Annual Macrophage-Directed Therapies Summit in Boston on October 2nd. Christine will provide key insights into IOMX-0675, our highly differentiated, fully human, cross-specific antibody targeting LILRB1 and LILRB2. In the presentation, Christine will discuss how IOMX-0675 effectively repolarizes the tumor microenvironment, resulting in potent tumor cell killing both 𝘪𝘯 𝘷𝘪𝘵𝘳𝘰 and 𝘪𝘯 𝘷𝘪𝘷𝘰. Also, Christine will highlight IOMX-0675's unique binding profile, which selectively antagonizes the immunosuppressive receptors LILRB1 and LILRB2 while sparing the immuno-activating family members. This differentiation results in superior macrophage repolarization and immune cell activation compared to other antibodies. 🔬   📢 Stay tuned for further updates!   Hanson Wade Group #CancerResearch #Macrophages #immunotherapy #ImmunoOncology

73

Looking forward to attending #ASH2024 this year. Let's connect and I can share with you how TD2 can support your next trial. 🔗https://hubs.li/Q02YXgqv0 #HematologyOncology #ClinicalTrials #OncologyCRO #BloodCancerResearch #DrugDevelopment #PrecisionOncology #ClinicalTrialSolutions

1

When evaluating eIRB systems, be sure to consider the needs of ALL institutional stakeholders - not just the IRB users. Read our blog from Advarra expert Faith Bertrand, CIP for advice bon assessing and implementing these technologies.

5

That’s a wrap on American Society of Clinical Oncology (ASCO) 2024!   Looking for a quick recap? Check out our latest blog “Top News from Biggest Players at ASCO 2024” to see a summary of key data and takeaways.   https://lnkd.in/eFZm_kjy   #ASCO24 #Oncology #AdelphiResearch #MarketResearch

65

🚨 Webinar Announcement: Improving Outcomes and Access to Precision Medicine🚨- https://lnkd.in/eSvkPZPG Despite groundbreaking advances in precision medicine, a critical gap remains: the lack of diverse representation in genomic data, leading to unequal healthcare outcomes—especially for people of color. 🔬 What is the impact? Genomic testing is a cornerstone of modern medicine, yet current databases are largely based on data from individuals of European descent. This leaves underrepresented populations at a disadvantage, with less effective treatments and limited access to life-saving innovations. 💡What you’ll learn: 1️⃣ Understanding the genomic testing gap and the structural barriers in healthcare 2️⃣ How to advance precision medicine for all, ensuring inclusivity 3️⃣ Practical strategies for improving access, including policy changes, community engagement, and innovative healthcare models 📅 Date: Thursday, 21st November, 2024 ⏰ Time: 12:00pm - 1:00pm ET 📍 Location: Zoom (Register Here https://lnkd.in/eSvkPZPG) Let’s work together to create a healthcare system that serves everyone. #PrecisionMedicine #GenomicTesting #HealthEquity

15

1 Comment

In today's edition of the NPC Healthbiz Weekly newsletter from the National Pharmaceutical Congress: The #pharmaceutical industry faces a critical challenge: delivering medicines to the world's poorest populations. While successful in many areas, our current approaches fall short in addressing global health disparities. Some key considerations: 1. Rethink global access strategies 2. Invest in infrastructure in developing regions 3. Apply lessons from Covid-19 vaccine distribution So, here's a question: Looking at the challenges of 2025, isn't it time the industry innovated its approach to ensure life-saving therapies reach those who need them most, regardless of geography or economic status? NPC Healthbiz Weekly is created by Chronicle Companies. Let us know what you think. https://lnkd.in/g-CQaGNb #lifesciences #leadership #pharmainnovation #globalhealth

4

For executives at rare disease drug developers, there remains uncertainty on how to best manage IRA risk in the context of product strategy. The IRA forces us to reconsider the traditional new product planning playbooks and instead incorporate a more nuanced assessment of IRA risk into decision making regarding indication prioritization, clinical development strategy, and forecasting. In our latest blog, we offer a framework to incorporate IRA risk into new product planning with our colleagues at Parexel. Read here: https://bit.ly/3xUFpXo Olivia (Dickey) Foroughi, MPH, Douglas Mullen, Brian M. Duda, Carrie Jones #raredisease #orphandrug #newproductplanning #NPP

14

1 Comment

In the rare disease space, every launch decision counts. Transform complexity into a strategy to navigate expedited pathways, manage risk, and avoid launch delays. Hear from our experts Kapil Raina, Brian Williams, and Chris Zealey: https://lnkd.in/eYHYwDS5 #MarketAccess #MedicalAffairs #LaunchExcellence #AskHerspiegel

6

Read how Klein Hersh partnered with a publicly traded biotech organization to fill three high-level interim consulting leadership roles across clinical development, medical writing, and biostatistics to drive key initiatives on tight deadlines. https://lnkd.in/eFyPTDN8

9

1 Comment

Who should have #genetictesting for #breastcancer? My Gene Counsel CEO, Ellen Matloff, shares a list of risk factors in an updated article with Everyday Health. This article can be a resource for you and your patients, who are pondering genetic testing. https://hubs.li/Q02w3gGc0 #GeneChat #PrecisionMedicine

1

In September, CAPDM submitted its response to the PMPRB - Patented Medicine Prices Review Board on Shaping the Future: A Discussion Guide for PMPRB Phase 2 Consultations on New Guidelines, highlighting our concerns around new drug pricing guidelines. Today, Angelique Berg, President & CEO, participated in a virtual stakeholder meeting to further discuss our recommendations. While fair drug pricing is essential, lowering prices without considering the impact on the pharmaceutical distribution network could jeopardize access to vital medications—particularly in rural communities. Read our key concerns and recommendations here: https://lnkd.in/eU73szpw Together, we can protect both affordability and accessibility. Let’s build a sustainable future for pharmaceutical distribution in Canada! #CdnHealth #Pharmacy #SupplyChain #CdnPoli

28

Join Blake Mandell from Transcend Therapeutics at the upcoming Fierce Biotech Summit on Sept 30 - Oct 1 in Boston as he shares his expertise in groundbreaking biotech innovations and advancements. Register now and save up to $500 with the Early Bird Rate: https://ow.ly/uTAE50SyYgy Learn, Network and Connect over two jam-packed days with 500+ industry leaders and gain valuable insights into the future landscape of biotech. Stay Updated on all our events by following Fierce Life Sciences Events #FierceBiotechSummit #WeAreFierce #FierceBiotech #FierceBiotechSummit #BiotechInnovation #LifeSciences #PharmaIndustry #BiotechLeaders #Biotech2024 #BiotechTrends

3

New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare

3

We want to call your attention to a timely new series on AJMC® Peer Exchange® peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on important issues facing today’s managed care professionals. Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads an expert panel discussion on the use of CDK4/6 inhibitors in high-risk early breast cancer. With insights from renowned experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO, this series covers crucial updates, best practices in managing toxicity profiles, and navigating financial challenges to optimize patient outcomes. Don't miss out on this opportunity to learn about: - Factors influencing decisions to prescribe CDK4/6 inhibitors - Analysis of the monarchE and NATALEE trial results - Sequencing considerations with CDK4/6 inhibitors - Differences in toxicity profiles between abemaciclib and ribociclib - The impact of different endocrine therapies on toxicities Watch the series here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare #CDK46Inhibitors #Oncology #PatientCare #MedicalUpdates

2